Recombinant Human PD-1 Fc Chimera Protein, CF
Recombinant Human PD-1 Fc Chimera Protein, CF Summary
| Human PD-1 (Leu25-Gln167) Accession # Q15116 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
1086-PD
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Image
View Larger
When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is coated at 0.1 µg/mL, Recombinant Human B7-H1/PD-L1 Fc Chimera (Catalog # 156-B7) binds with a typical ED50of 0.15-0.75 µg/mL.
Reconstitution Calculator
Background: PD-1
Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature mouse PD-1 consists of a 149 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 21 aa transmembrane domain, and a 98 aa cytoplasmic region. The mouse PD-1 ECD shares 65% aa sequence identity with the human PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces
co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13).
- Ishida, Y. et al. (1992) EMBO J. 11:3887.
- Sharpe, A.H. and G. J. Freeman (2002) Nat. Rev. Immunol. 2:116.
- Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
- Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
- Watanabe, N et al. (2003) Nat. Immunol. 4:670.
- Zhang, X. et al. (2004) Immunity 20:337.
- Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
- Nishimura, H et al. (1996) Int. Immunol. 8:773.
- Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
- Butte, M.J. et al. (2007) Immunity 27:111.
- Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
- Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99: 12293.
- Nogrady, B. (2014) Nature 513:S10.
Citations for Recombinant Human PD-1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
18
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
Authors: M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue
Sci Rep, 2019;9(1):16678.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
Authors: M Passariell, AM D'Alise, A Esposito, C Vetrei, G Froechlich, E Scarselli, A Nicosia, C De Lorenzo
Sci Rep, 2019;9(1):13125.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression
Authors: W Wang, NM Chapman, B Zhang, M Li, M Fan, RN Laribee, MR Zaidi, LM Pfeffer, H Chi, ZH Wu
Cancer Res., 2019;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
Authors: N Zhang, Y Dou, L Liu, X Zhang, X Liu, Q Zeng, Y Liu, M Yin, X Liu, H Deng, D Song
EBioMedicine, 2019;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
Authors: B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, JM Hsu, LC Chan, Z Zha, H Li, MC Hung
Am J Cancer Res, 2018;8(9):1837-1846.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Authors: CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, LC Chan, T Kim, SS Chang, HH Lee, CK Chou, YL Liu, HC Yeh, EP Perillo, AK Dunn, CW Kuo, KH Khoo, JL Hsu, Y Wu, JM Hsu, H Yamaguchi, TH Huang, AA Sahin, GN Hortobagyi, SS Yoo, MC Hung
Cancer Cell, 2018;33(2):187-201.e10.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
Authors: H Wang, H Yao, C Li, H Shi, J Lan, Z Li, Y Zhang, L Liang, JY Fang, J Xu
Nat. Chem. Biol., 2018;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
JCI Insight, 2018;3(19):.
Species: Human
Sample Types: Plasma
Applications: ELISA (Capture) -
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
Nature, 2016;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Nat Commun, 2016;7(0):12632.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Rapid PD-L1 detection in tumors with PET using a highly specific peptide
Authors: Samit Chatterjee
Biochem. Biophys. Res. Commun, 2016;0(0):.
Applications: Bioassay -
B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.
Authors: Yang Y, Wu K, Zhao E, Li W, Shi L, Xie G, Jiang B, Wang Y, Li R, Zhang P, Shuai X, Wang G, Tao K
Oncol Lett, 2015;9(4):1833-1838.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
PLoS ONE, 2014;9(12):e113396.
Species: Human
Sample Types: Serum
Applications: ELISA (Standard) -
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Authors: Steidl C, Shah SP, Woolcock BW
Nature, 2011;471(7338):377-81.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression.
Authors: Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, Hur DY
J. Immunol., 2008;181(9):6158-69.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis.
Authors: Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK
J. Neuroimmunol., 2007;193(1):149-55.
Species: N/A
Sample Types: N/A
Applications: ELISA (Standard) -
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
J. Immunol., 2006;177(12):8844-50.
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Authors: Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, Stankevich E, Pons A, Salay T, McMiller T, Gilson M, Wang C, Selby M, Taube J, Anders R, Chen L, Korman A, Pardoll D, Lowy I, Topalian S
J Clin Oncol, 0;28(19):3167-75.
Species: Human
Sample Types: Serum
Applications: ELISA (Capture)
FAQs
-
The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?
Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.
-
What is the recommended method for reconstitution of a lyophilized protein or antibody?
Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand. Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.
-
Are R&D Systems recombinant proteins and antibodies sterile?
Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.
Recombinant Proteins
Reconstitution Buffers
Reviews for Recombinant Human PD-1 Fc Chimera Protein, CF
Average Rating: 4.7 (Based on 9 Reviews)
Have you used Recombinant Human PD-1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Cells expressing a negative control (left) or hPD-L1 mCherry (right) were treated with 0.25 ug of hPD-1 hIgG1. Cells were analyzed by flow cytometry with binding detected using an anti-human 488 secondary antibody.
Sorry that I just rate the catalog based on my alike recombinant PD1 peptide. I have one question for the peptide. Owing the Ig like peptide with Fc fragment. So when we detect it binding to PDL1 on cell assay, it is difficult to get definite conclusion if it is PDL1 binding or others.
My protocol is as below:
-Cells with PDL1 high level was treated by PD1 like peptide,
-4degree 1hr
-collected and lysis
-WB by anti-IgG to Fc recognization.
Result: weak signal. you don't know if it is non-specific binding
R&D Systems response: Thank you so much for taking the time to share your experience using R&D Systems Proteins. We value your opinion and use our online reviews as testimonials from our customers of the quality of our products. Our technical service representatives work hard to resolve any issues with our products when our customers are unhappy. We have reached out to offer additional support with this product and are unable to reach you. Please contact a technical service representative at techsupport@bio-techne.com and allow us to further troubleshoot some of the concerns you have mentioned in your online review. We look forward to hearing from you.
